BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 8311001)

  • 1. Adenocarcinoma of the esophagus and gastroesophageal junction. Clinical and pathologic assessment of response to induction chemotherapy.
    Adelstein DJ; Rice TW; Boyce GA; Sivak MV; Van Kirk MA; Kirby TJ; van Stolk RU; Bukowski RM
    Am J Clin Oncol; 1994 Feb; 17(1):14-8. PubMed ID: 8311001
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intensive preoperative chemotherapy with colony-stimulating factor for resectable adenocarcinoma of the esophagus or gastroesophageal junction.
    Ajani JA; Roth JA; Ryan MB; Putnam JB; Pazdur R; Levin B; Gutterman JU; McMurtrey M
    J Clin Oncol; 1993 Jan; 11(1):22-8. PubMed ID: 8418237
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A three-step strategy of induction chemotherapy then chemoradiation followed by surgery in patients with potentially resectable carcinoma of the esophagus or gastroesophageal junction.
    Ajani JA; Komaki R; Putnam JB; Walsh G; Nesbitt J; Pisters PW; Lynch PM; Vaporciyan A; Smythe R; Lahoti S; Raijman I; Swisher S; Martin FD; Roth JA
    Cancer; 2001 Jul; 92(2):279-86. PubMed ID: 11466680
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of pre- and postoperative chemotherapy for resectable adenocarcinoma of the esophagus or gastroesophageal junction.
    Ajani JA; Roth JA; Ryan B; McMurtrey M; Rich TA; Jackson DE; Abbruzzese JL; Levin B; DeCaro L; Mountain C
    J Clin Oncol; 1990 Jul; 8(7):1231-8. PubMed ID: 2358838
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Esophageal carcinoma: esophageal ultrasound assessment of preoperative chemotherapy.
    Rice TW; Boyce GA; Sivak MV; Adelstein DJ; Kirby TJ
    Ann Thorac Surg; 1992 Jun; 53(6):972-7. PubMed ID: 1596158
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preoperative induction of CPT-11 and cisplatin chemotherapy followed by chemoradiotherapy in patients with locoregional carcinoma of the esophagus or gastroesophageal junction.
    Ajani JA; Walsh G; Komaki R; Morris J; Swisher SG; Putnam JB; Lynch PM; Wu TT; Smythe R; Vaporciyan A; Faust J; Cohen DS; Nivers R; Roth JA
    Cancer; 2004 Jun; 100(11):2347-54. PubMed ID: 15160337
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety, efficacy, and long-term follow-up evaluation of perioperative epirubicin, Cisplatin, and capecitabine chemotherapy in esophageal resection for adenocarcinoma.
    van der Sluis PC; Ubink I; van der Horst S; Boonstra JJ; Voest EE; Ruurda JP; Borel Rinkes IH; Wiezer MJ; Schipper ME; Siersema PD; Los M; Lolkema MP; van Hillegersberg R
    Ann Surg Oncol; 2015 May; 22(5):1555-63. PubMed ID: 25564156
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effective radiochemotherapy with cisplatin and etoposide for the management of patients with locally inoperable and metastatic esophageal carcinoma.
    Hejna M; Kornek GV; Schratter-Sehn AU; Zach M; Schoder M; Raderer M; Rosen H; Schiessel R; Scheithauer W
    Cancer; 1996 Oct; 78(8):1646-50. PubMed ID: 8859175
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endoscopic ultrasonography in the quantitative assessment of response to chemotherapy in patients with adenocarcinoma of the esophagus and esophagogastric junction.
    Roubein LD; DuBrow R; David C; Lynch P; Fornage B; Ajani J; Roth J; Levin B
    Endoscopy; 1993 Nov; 25(9):587-91. PubMed ID: 8119209
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase 2 study of SP1049C, doxorubicin in P-glycoprotein-targeting pluronics, in patients with advanced adenocarcinoma of the esophagus and gastroesophageal junction.
    Valle JW; Armstrong A; Newman C; Alakhov V; Pietrzynski G; Brewer J; Campbell S; Corrie P; Rowinsky EK; Ranson M
    Invest New Drugs; 2011 Oct; 29(5):1029-37. PubMed ID: 20179989
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 5-Fluorouracil, adriamycin, and mitomycin C in adenocarcinoma of the esophagus or gastroesophageal junction tumors.
    Khansur T; Allred C; Tavassoli M
    Am J Clin Oncol; 1994 Dec; 17(6):506-8. PubMed ID: 7977170
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preoperative and postoperative combination chemotherapy for potentially resectable gastric carcinoma.
    Ajani JA; Mayer RJ; Ota DM; Steele GD; Evans D; Roh M; Sugarbaker DJ; Dumas P; Gray C; Vena DA
    J Natl Cancer Inst; 1993 Nov; 85(22):1839-44. PubMed ID: 8230264
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NeoFLOT: Multicenter phase II study of perioperative chemotherapy in resectable adenocarcinoma of the gastroesophageal junction or gastric adenocarcinoma-Very good response predominantly in patients with intestinal type tumors.
    Schulz C; Kullmann F; Kunzmann V; Fuchs M; Geissler M; Vehling-Kaiser U; Stauder H; Wein A; Al-Batran SE; Kubin T; Schäfer C; Stintzing S; Giessen C; Modest DP; Ridwelski K; Heinemann V
    Int J Cancer; 2015 Aug; 137(3):678-85. PubMed ID: 25530271
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase II trial of induction epirubicin, oxaliplatin, and fluorouracil, followed by surgery and postoperative concurrent cisplatin and fluorouracil chemoradiotherapy in patients with locoregionally advanced adenocarcinoma of the esophagus and gastroesophageal junction.
    McNamara MJ; Adelstein DJ; Bodmann JW; Greskovich JF; Ives DI; Mason DP; Murthy SC; Rice TW; Saxton JP; Sohal D; Stephans K; Rodriguez CP; Videtic GM; Rybicki LA
    J Thorac Oncol; 2014 Oct; 9(10):1561-7. PubMed ID: 25170643
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I/II trial of preoperative oxaliplatin, docetaxel, and capecitabine with concurrent radiation therapy in localized carcinoma of the esophagus or gastroesophageal junction.
    Spigel DR; Greco FA; Meluch AA; Lane CM; Farley C; Gray JR; Clark BL; Burris HA; Hainsworth JD
    J Clin Oncol; 2010 May; 28(13):2213-9. PubMed ID: 20351330
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A pilot trial of S-1 plus irinotecan chemotherapy for esophageal adenocarcinoma.
    Nakajima Y; Fujiwara N; Ryotokuji T; Ohta S; Okada T; Miyawaki Y; Hoshino A; Jirawat S; Tokairin Y; Kawada K; Nishikage T; Nagai K; Kawano T
    Hepatogastroenterology; 2012 Oct; 59(119):2182-5. PubMed ID: 22366525
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase II evaluation of high dose cisplatin and etoposide in patients with advanced esophageal adenocarcinoma.
    Spiridonidis CH; Laufman LR; Jones JJ; Gray DJ; Cho CC; Young DC
    Cancer; 1996 Nov; 78(10):2070-7. PubMed ID: 8918399
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of concurrent chemotherapy, accelerated fractionation radiation, and surgery for patients with esophageal carcinoma.
    Adelstein DJ; Rice TW; Becker M; Larto MA; Kirby TJ; Koka A; Tefft M; Zuccaro G
    Cancer; 1997 Sep; 80(6):1011-20. PubMed ID: 9305700
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II multicentre study of efficacy and feasibility of dose-intensified preoperative weekly cisplatin, epirubicin, and paclitaxel (PET) in resectable gastroesophageal cancer.
    Jary M; Ghiringhelli F; Jacquin M; Fein F; Nguyen T; Cleau D; Nerich V; El Gani M; Mathieu P; Valmary-Degano S; Arnould L; Lassabe C; Lamfichekh N; Fratté S; Paget-Bailly S; Bonnetain F; Borg C; Kim S
    Cancer Chemother Pharmacol; 2014 Jul; 74(1):141-50. PubMed ID: 24824852
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Irinotecan/cisplatin in advanced, treated gastric or gastroesophageal junction carcinoma.
    Ajani JA; Baker J; Pisters PW; Ho L; Mansfield PF; Feig BW; Charnsangavej C
    Oncology (Williston Park); 2002 May; 16(5 Suppl 5):16-8. PubMed ID: 12109800
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.